Results 111 to 120 of about 7,648 (236)

MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1

Oncology Reports, 2018
Breast cancer is the leading cause of cancer-related deaths in females worldwide. Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancer cases and has a poorer prognosis than other subtypes. Moreover, the treatment for breast cancer, especially for TNBC, remains unsatisfactory.
Wang, Yongxia, Zhang, Zheying, Wang, Jianqiang   +2 more
openaire   +3 more sources

cIMPACT‐NOW update 11: Proposal on adaptation of diagnostic criteria for IDH‐ and H3‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors

Brain Pathology, Volume 36, Issue 1, January 2026.
Abstract The Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (cIMPACT‐NOW) updates provide guidelines for the diagnosis of central nervous system (CNS) tumors and suggestions for future World Health Organization (WHO) classification.
Pieter Wesseling, David Capper, Guido Reifenberger, Chitra Sarkar, Cynthia Hawkins, Arie Perry, Bette Kleinschmidt‐DeMasters, Takashi Komori, Werner Paulus, Vani Santosh, Martin van den Bent, Michael Weller, Stefan M. Pfister, Uri Tabori, Dominique Figarella‐Branger, Brent A. Orr, David N. Louis   +16 more
wiley   +1 more source

Update On Fragment Screening Of Acvr1 Co_Crystallised With Ldn_193189

, 2018
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no.
Adamson, Roslin, Matteucci, Mizio, Brennan, Paul, Bullock, Alex   +3 more
openaire   +1 more source

ACVR1 Gene Mutation in Sporadic Korean Patients with Fibrodysplasia Ossificans Progressiva

Journal of Korean Medical Science, 2009
Fibrodysplasia ossificans progressiva (FOP; OMIM 135100) is a rare but extremely disabling genetic disorder of the skeletal system, and is characterized by the progressive development of ectopic ossification of skeletal muscles and subsequent joint ankylosis.
Lee, Dong Yeon, Cho, Tae-Joon, Lee, Hye Ran, Park, Moon Seok, Yoo, Won Joon, Chung, Chin Youb, Choi, In Ho   +6 more
openaire   +2 more sources

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Biomedicines
Fibrodysplasia ossificans progressiva (FOP) is a debilitating genetic disorder characterized by recurrent episodes of heterotopic ossification (HO) formation in muscles, tendons, and ligaments.
Loreilys Mejias Rivera, Eileen M. Shore, Foteini Mourkioti   +2 more
doaj   +1 more source

Comprehensive molecular characterisation of epilepsy-associated glioneuronal tumours [PDF]

, 2017
Glioneuronal tumours are an important cause of treatment-resistant epilepsy. Subtypes of tumour are often poorly discriminated by histological features and may be difficult to diagnose due to a lack of robust diagnostic tools.
Apps, J, Brooks, T, Chalker, J, Cross, JH, Forshew, T, Gutteridge, A, Ham, J, Hargrave, D, Harkness, W, Hubank, M, Izquierdo Delgado, E, Jacques, TS, Keeley, A, Kristiansen, M, Mifsud, W, Stone, TJ, Thom, M, Tisdall, M, Virasami, A, Wilkhu, L   +19 more
core   +2 more sources

DIPG-22. A NOVEL ROLE FOR ACVR1/ALK2 IN REGULATING CHOLESTEROL BIOSYNTHESIS PROVIDES A NEW COMBINATORIAL THERAPEUTIC APPROACH FOR PATIENTS WITH DMG

Neuro-Oncology
BACKGROUND The discovery of somatic mutations in ACVR1, which encodes the serine/threonine kinase ALK2, in 20-25% of diffuse midline glioma H3K27-altered (DMG-H3K27) patients has led to the development of numerous chemotypes of ALK2 inhibitor (ALK2i ...
Aimée du Chatinier, M. Meel, Piotr Waranecki, D. Metselaar, E. Hulleman   +4 more
semanticscholar   +1 more source

Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study

European Journal of Haematology, Volume 116, Issue 1, Page 23-30, January 2026.
ABSTRACT Momelotinib, a novel JAK1/2 inhibitor with inhibitory activities on activin A receptor type I, has shown breakthrough clinical efficacy in patients with myelofibrosis (MF) and anemia, a disease‐related manifestation of challenging management. In this retrospective real‐life multicenter Italian study, we investigated the safety and efficacy of ...
Maria Carmen Martorelli, Novella Pugliese, Maria Di Perna, Danilo De Novellis, Assunta Lombardi, Laura De Fazio, Giuseppina Loglisci, Ilaria Peluso, Matteo Molica, Carolina Copia, Alessandra Ricco, Antonella Bruzzese, Francesco Mendicino, Vincenza De Fazio, Teresa Maria Santeramo, Rosario Bianco, Giuseppe Monaco, Raffaele Fontana, Roberto Guariglia, Bianca Serio, Serena Luponio, Anna Maria Della Corte, Antonella Malandrini, Valentina Giudice, Ferdinando Frigeri, Giuseppe Tarantini, Attilio Guarini, Massimo Gentile, Pellegrino Musto, Mario Annunziata, Nicola Di Renzo, Marco Rossi, Catello Califano, Fabrizio Pane, Carmine Selleri   +34 more
wiley   +1 more source

Purification of ACVR1 for fine screening with M4K compounds_Nov_2018

, 2018
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no.
Adamson, Roslin, Brennan, Paul, Mateucci, Mizio, Bullock, Alex   +3 more
openaire   +1 more source

Deficient Signaling via Alk2 (Acvr1) Leads to Bicuspid Aortic Valve Development

PLoS ONE, 2012
Bicuspid aortic valve (BAV) is the most common congenital cardiac anomaly in humans. Despite recent advances, the molecular basis of BAV development is poorly understood. Previously it has been shown that mutations in the Notch1 gene lead to BAV and valve calcification both in human and mice, and mice deficient in Gata5 or its downstream target Nos3 ...
Penny S Thomas, Somyoth Sridurongrit, Pilar Ruiz-Lozano, Vesa Kaartinen   +3 more
openaire   +4 more sources